Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Full model: Adjusted for sex, age, inclusion date, diabetes duration, Charlson Comorbidity Index, any diabetic complications, previous falls, inflammatory bowel disease, ever insulin use, ever glucocorticoid use, hypertension, kidney disease, alcohol, smoking and obesity, and stratified by osteoporosis
Glucagon-like Peptide-1 receptor agonist ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) neurotoxicity through enhancing mitophagy flux and reducing -Synuclein and oxidative stress
Resolution-season motivation is valuable channeling it toward approaches with stronger evidence bases may produce better outcomes
Caruso I, Di Gioia L, Di Molfetta S et al (2023) Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
Naltrexone and alcohol dependence
US$ 25.39
US$ 22.01
US$ 28.50
US$ 21.76
